Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-26
2011-07-26
Henley, III, Raymond (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07985757
ABSTRACT:
An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.
REFERENCES:
patent: 4227006 (1980-10-01), Okamoto et al.
patent: 5214052 (1993-05-01), Ofuchi et al.
patent: 5506241 (1996-04-01), Mano et al.
patent: 5679690 (1997-10-01), Andre et al.
patent: 5849843 (1998-12-01), Laurin et al.
patent: 5998019 (1999-12-01), Rosenbaum et al.
patent: 6087375 (2000-07-01), Bridon et al.
patent: 0 565 897 (1993-10-01), None
patent: 0 608 828 (1994-08-01), None
patent: 0 608 831 (1994-08-01), None
patent: 0 621 036 (1994-10-01), None
patent: 0 669 131 (1995-08-01), None
patent: 2005/009361 (2010-03-01), None
Remington—The Science and Practice of Pharmacy 20th Edition, 2000, 9 pages.
GSKARL3—Search performed for acetic acid dissolve argatroban, [online], [retrieved on Aug. 18, 2008], Retrieved from the Internet:<:URL:http://us.gsk.com/products/assets/us—argatroban.pdf>.
Burgos Richard A.
Owoo George
Baxter Healthcare S.A.
Baxter International Inc.
Henley III Raymond
K&L Gates LLP
LandOfFree
Argatroban formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Argatroban formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Argatroban formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706760